3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
80
Neoplasm Metastasis
6
Neoplasms
3
Breast Neoplasms, Male
3
Arthralgia
2
Triple Negative Breast Neoplasms
1
Sleep Wake Disorders
1
Skin Diseases
1
Prostatic Neoplasms
1
Post Menopausal Women With Early Breast Cancer
1
Pancreatic Neoplasms
1
Pain
1
Ovarian Neoplasms
1
Obesity
1
Metastatic Beast Cancer
1
Mammary Neoplasms, Animal
1
Lymphoma
1
Lethal Congenital Contracture Syndrome 2
1
Invasive Early Breast Cancer
1
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
1
Fatigue
1
Estrogen-receptor Positive Invasive Metastatic Breast Cancer
1
Endometrial Neoplasms
1
Endometrial Hyperplasia
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Diseases
1
Breast Carcinoma In Situ
1
Breast Cancer Metastatic
1
Advanced Breast Carcinoma
1
Interventions
binimetinib
2
ipatasertib
1
exemestane
1
encorafenib
1
baricitinib
1
atezolizumab
1
Vemurafenib
1
VP-102
1
Paclitaxel
1
Fluorouracil
1
Everolimus
1
Dacarbazine
1
Cantharidin
1
BF-200 ALA
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Skin Diseases
×
exemestane
×
Clear all
NCT01743560
2019-07-18
4EVERUK
Novartis
Phase 4
Completed
52 enrolled
16 charts